Logo image of TVTX

TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis

NASDAQ:TVTX - Nasdaq - US89422G1076 - Common Stock - Currency: USD

17.26  -0.02 (-0.12%)

Fundamental Rating

3

TVTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. TVTX has a bad profitability rating. Also its financial health evaluation is rather negative. TVTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TVTX has reported negative net income.
In the past year TVTX has reported a negative cash flow from operations.
TVTX had negative earnings in each of the past 5 years.
TVTX had a negative operating cash flow in each of the past 5 years.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

TVTX has a better Return On Assets (-30.44%) than 65.45% of its industry peers.
TVTX has a worse Return On Equity (-516.25%) than 78.73% of its industry peers.
Industry RankSector Rank
ROA -30.44%
ROE -516.25%
ROIC N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

TVTX has a Gross Margin of 96.89%. This is amongst the best in the industry. TVTX outperforms 97.09% of its industry peers.
In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
TVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TVTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TVTX has more shares outstanding
TVTX has a worse debt/assets ratio than last year.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TVTX has an Altman-Z score of -2.03. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TVTX (-2.03) is comparable to the rest of the industry.
A Debt/Equity ratio of 9.50 is on the high side and indicates that TVTX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 9.50, TVTX is doing worse than 84.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 9.5
Debt/FCF N/A
Altman-Z -2.03
ROIC/WACCN/A
WACC9.06%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

A Current Ratio of 2.00 indicates that TVTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.00, TVTX is doing worse than 76.00% of the companies in the same industry.
A Quick Ratio of 1.98 indicates that TVTX should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.98, TVTX is not doing good in the industry: 74.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.98
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

TVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.11%, which is quite impressive.
The Revenue has grown by 87.94% in the past year. This is a very strong growth!
Measured over the past years, TVTX shows a small growth in Revenue. The Revenue has been growing by 5.87% on average per year.
EPS 1Y (TTM)58.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.62%
Revenue 1Y (TTM)87.94%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%111.49%

3.2 Future

Based on estimates for the next years, TVTX will show a very strong growth in Earnings Per Share. The EPS will grow by 27.97% on average per year.
Based on estimates for the next years, TVTX will show a very strong growth in Revenue. The Revenue will grow by 37.86% on average per year.
EPS Next Y73.02%
EPS Next 2Y45.21%
EPS Next 3Y36.93%
EPS Next 5Y27.97%
Revenue Next Year69.15%
Revenue Next 2Y55.77%
Revenue Next 3Y47.43%
Revenue Next 5Y37.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
TVTX is valuated quite expensively with a Price/Forward Earnings ratio of 38.72.
Based on the Price/Forward Earnings ratio, TVTX is valued cheaper than 90.55% of the companies in the same industry.
TVTX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 33.87.
Industry RankSector Rank
PE N/A
Fwd PE 38.72
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TVTX's earnings are expected to grow with 36.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.21%
EPS Next 3Y36.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TVTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (8/12/2025, 10:50:40 AM)

17.26

-0.02 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners116.52%
Inst Owner Change1.68%
Ins Owners0.84%
Ins Owner Change1.48%
Market Cap1.53B
Analysts84.55
Price Target34.24 (98.38%)
Short Float %14.75%
Short Ratio8.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.58%
Min EPS beat(2)15.26%
Max EPS beat(2)53.91%
EPS beat(4)2
Avg EPS beat(4)10.22%
Min EPS beat(4)-27.29%
Max EPS beat(4)53.91%
EPS beat(8)3
Avg EPS beat(8)-89.98%
EPS beat(12)5
Avg EPS beat(12)-61.75%
EPS beat(16)5
Avg EPS beat(16)-51.54%
Revenue beat(2)2
Avg Revenue beat(2)7.39%
Min Revenue beat(2)3.29%
Max Revenue beat(2)11.48%
Revenue beat(4)3
Avg Revenue beat(4)4.18%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)11.48%
Revenue beat(8)5
Avg Revenue beat(8)-5.65%
Revenue beat(12)8
Avg Revenue beat(12)-6.02%
Revenue beat(16)9
Avg Revenue beat(16)-10.33%
PT rev (1m)-1.84%
PT rev (3m)-0.28%
EPS NQ rev (1m)-6.35%
EPS NQ rev (3m)28.25%
EPS NY rev (1m)0%
EPS NY rev (3m)24.69%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)13.49%
Revenue NY rev (1m)-1.37%
Revenue NY rev (3m)1.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 38.72
P/S 4.59
P/FCF N/A
P/OCF N/A
P/B 46.8
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)0.45
Fwd EY2.58%
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS3.76
BVpS0.37
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.44%
ROE -516.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.89%
FCFM N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 9.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.47%
Cap/Sales 12.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.98
Altman-Z -2.03
F-Score4
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.62%
EPS Next Y73.02%
EPS Next 2Y45.21%
EPS Next 3Y36.93%
EPS Next 5Y27.97%
Revenue 1Y (TTM)87.94%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%111.49%
Revenue Next Year69.15%
Revenue Next 2Y55.77%
Revenue Next 3Y47.43%
Revenue Next 5Y37.86%
EBIT growth 1Y46.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.54%
EBIT Next 3Y37.49%
EBIT Next 5Y33.05%
FCF growth 1Y45.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.8%
OCF growth 3YN/A
OCF growth 5YN/A